Vascular endothelial growth factor and microvessel density for detection and prognostic evaluation of invasive breast cancer ⁎

Author:

Yang Lukui1,Li Long2,Cui Xiangyu3,Yang Dalei2

Affiliation:

1. Department of Health Care Center, Rizhao Entry-Exit Inspection and Quarantine Bureau, Rizhao 276826, China

2. Department of General Surgery, The People’s Hospital of Rizhao City, Rizhao 276826, China

3. Blood Collection Department, Rizhao Central Blood Station, Rizhao 276826, China

Abstract

Abstract Objective The purpose of this study was to evaluate the distribution of vascular endothelial growth factor (VEGF) and CD105-microvessel density (MVD) in invasive breast carcinomas. We also aimed to analyze the relationship between VEGF and MVD expression with other standard prognostic parameters associated with invasive breast cancer, such as size, grade, stage of the cancer, metastases, and tumor recurrence. Methods Immunohistochemistry via the Ultra SensitiveTM S-P method was used to detect VEGF and MVD expression in 128 cases of invasive breast carcinoma. Specimens were evaluated for CD105 expression. Positively stained microvessels were counted in dense vascular foci under 400× magnification. MVD in the peripheral area adjacent to the lesion and in the central area within the lesion in invasive breast carcinomas and benign leisions groups were also assessed. Fifty cases of benign breast disease tissue were selected as the control group. Results Results showed that 64.1% of invasive breast cancer samples were VEGF-positive, higher than in benign breast disease tissue (22.0%, P < 0.05). There was a positive correlation between VEGF overexpression and histological grade, lymph node metastasis, and distant metastasis of invasive breast cancer. VEGF expression was not related to age or size of the tumor (P > 0.05). MVD of the peripheral area adjacent to the lesion was significantly higher than those central area within the lesion in both invasive breast cancer and benign breast disease groups (P < 0.01 for each group). There were significant differences in the mean CD105-MVD, between invasive breast tumors with a histological grade of I or II and grade III; between tumors with lymph node or distant metastasis; and between patients with or without recurrence (P < 0.05). However, there was no difference in the mean MVD between the two age groups (≤ 50 years vs. > 50 years) or the two tumor diameter groups (≤ 2 cm vs. > 2 cm), P > 0.05. Conclusion Overexpression of VEGF and MVD may be important biological markers for invasion and lymph node and distant metastases of invasive breast cancer. Combined detection of the two tumor markers could provide better prognostic monitoring for disease recurrence and metastasis, as well as aid with clinical staging of breast tumors. Prediction of the risk for metastasis and recurrence, as well as recurrence patterns based on VEGF and MVD post-surgery, could aid design of better follow-up regimens and appropriate treatment strategies for breast cancer patients.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference11 articles.

1. Phase II trial of Loubo® (Lobaplatin) and pemetrexed for patients with metastatic breast cancer not responding to anthracycline or taxanes;Deng;Asian Pac J Cancer Prev,2013

2. Expression and significance of ER, PR, VEGF, CA15-3, CA125 and CEA in judging the prognosis of breast cancer;Zhang;Asian Pac J Cancer Prev,2013

3. Endoglin-a marker of vascular endothelial cell proliferation in cancer;Kopczyńska;Wspolczesna Onkol,2012

4. A comparative study of bone scan findings and serum levels of tumor marker CA153 in patients with breast carcinoma;Ghadge;Indian J Clin Biochem,2012

5. Clinical usefulness of assessing VEGF and soluble receptors sVEGFR-1 and sVEGFR-2 in women with breast cancer;Thielemann;Ann Agric Environ Med,2013

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3